Cochrane Library

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)

Hussein N, Weng SF, Kai J, Kleijnen J, Qureshi N

www.cochranelibrary.com

WILEY

T A B L E   O F   C O N T E N T S

[Intervention Review]

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease

Norita Hussein[1], Stephen F Weng[2], Joe Kai[2], Jos Kleijnen[3,4], Nadeem Qureshi[2]

[1]Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [2]Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK. [3]Kleijnen Systematic Reviews Ltd, York, UK. [4]School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands

Contact address: Nadeem Qureshi, Division of Primary Care, School of Medicine, University of Nottingham, 1307 The Tower, University Park Campus, Nottingham, NG9 2RD, UK. nadeem.qureshi@nottingham.ac.uk.

ABSTRACT

Background

Globally, about five per cent of children are born with congenital or genetic disorders. The most common autosomal recessive conditions are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease, with higher carrier rates in specific patient populations. Identifying and counselling couples at genetic risk of the conditions before pregnancy enables them to make fully informed reproductive decisions, with some of these choices not being available if genetic counselling is only offered in an antenatal setting.

Objectives

To assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease in healthcare settings when compared to usual care.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Registers. In addition, we searched for all relevant trials from 1970 (or the date at which the database was first available if after 1970) to date using electronic databases (MEDLINE, Embase, CINAHL, PsycINFO), clinical trial databases (National Institutes of Health, Clinical Trials Search portal of the World Health Organization, metaRegister of controlled clinical trials), and hand searching of key journals and conference abstract books from 1998 to date (*European Journal of Human Genetics, Genetics in Medicine, Journal of Community Genetics*). We also searched the reference lists of relevant articles, reviews and guidelines and also contacted subject experts in the field to request any unpublished or other published trials.

Date of latest search of the registers: 25 June 2015.

Date of latest search of all other sources: 10 December 2014.

Selection criteria

Any randomised or quasi-randomised control trials (published or unpublished) comparing reproductive outcomes of systematic preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease when compared to usual care.

Data collection and analysis

We identified 19 papers, describing 13 unique trials which were potentially eligible for inclusion in the review. However, after assessment, no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease were found.

Main results

No randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease were found.

Authors' conclusions

As no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were found for inclusion in this review, the research evidence for current policy recommendations is limited to non-randomised studies.

Information from well-designed, adequately powered, randomised trials is desirable in order to make more robust recommendations for practice. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic risk assessment.

P L A I N   L A N G U A G E   S U M M A R Y

Identifying carrier status for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease in non-pregnant women and their partners

Review question

We looked for evidence to show whether identifying people who are carriers for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease, before pregnancy leads to improving reproductive choice and pregnancy outcomes.

Background

Across the world, about five per cent of children are born with genetic disorders. These disorders can be passed down from parent to child. There are tests to identify the genetic risk of the most common genetic disorders (thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease) before pregnancy. In these disorders, called autosomal recessive conditions, the parents of affected children are 'carriers' of the condition, which means they do not usually have symptoms. All 'carrier' couples will have a 25 per cent chance of having an affected child. Risk assessment for these genetic disorders prior to pregnancy would benefit potential parents who may be carriers. This information would give the at-risk couple the opportunity to make fully informed decisions about family planning. However, genetic risk assessment before pregnancy may potentially have a negative psychological impact.

Search date

We last looked for evidence on 10 December 2014.

Study characteristics

We did not find any trials that we could include in this review.

Key results

Although no trials were identified in which volunteers would have equal chances of being in either group, there are several studies which are not so strictly designed which support current policy recommendations for genetic risk assessment prior to pregnancy in routine clinical practice. Any future trials need to consider legal, ethical and cultural barriers to implementation.

BACKGROUND

A glossary of terms is available as an appendix (Appendix 1).

Description of the condition

Genetic medicine is expanding into almost every aspect of health care; reproductive risk assessment during the preconception period is a prime example. Identifying genetic risks before pregnancy or conception might produce significant benefits, such as providing information about the risk of having children with genetic conditions and thus giving couples or prospective parents the opportunity to make more informed reproductive decisions. It has been estimated that a couple has a baseline risk of two to three per cent of having a child with a congenital or genetic disorder (Teeuw 2010). The probability of having an affected child increases when there is a family history of genetic disorders (Shapira 2006; Teeuw 2010). Globally, about five per cent of children are born with congenital or genetic disorders (WHO 1999).

Preconception risk assessment for autosomal recessive genetic disorders would benefit couples who may be carriers. The most common examples of these autosomal recessive disorders are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. In these disorders, such carriers are usually asymptomatic; however, their child will be affected if he or she inherits the affected genes from both parents. All carrier couples have a 25 per cent chance of having an affected child. These conditions have a high morbidity risk, are potentially life-threatening and have a significant psychological impact not only on the affected child, but also on their families or care givers. These diseases are also more prevalent in individuals of particular ethnic backgrounds (WHO 2000).

The need for medical care, as well as psychological interventions to offer behavioural and emotional support, imposes a potentially high economic and public health burden. In view of the magnitude of these conditions and their implications, there have been considerable efforts to identify the genetic reproductive risk for the four specified conditions and offer support to potential parents before the birth of an affected child. Women and couples at increased genetic risk, as well as healthcare professionals, have recognised the importance of preconception assessment (Boulton 1996; Henneman 2001; Locock 2008; Mennie 1998; Poppelaars 2004; Watson 1999; Wille 2004). To date, the practical experience of reproductive genetic risk assessment for autosomal recessive disorders focuses mainly on the antenatal and newborn period (Qureshi 2004). Identifying genetic reproductive risk during the antenatal period leaves the couple a short period of time to make difficult or limited choices, such as terminating the pregnancy or continuing with the pregnancy and caring for the affected child (Dormandy 2008). Identifying couples who have confirmed genetic carrier status before conception provides an opportunity for individuals or couples to make fully informed reproductive choices including avoiding pregnancy, pre-implantation diagnosis and *in vitro* fertilization, arranging early prenatal diagnosis and antenatal care and also considering adoption of a child (Jones 2002; Wille 2004).

Thalassaemia

According to the WHO, every year 300,000 infants are born with major haemoglobin disorders, the most common being thalassaemia and sickle cell disease (WHO 1999). Thalassaemia is characterised by the defects or absence of synthesis in one of the two globin chains (α or β) which form the normal adult human haemoglobin molecule; this leads to haemolytic anaemia (Peters 2012). Thalassaemia can be diagnosed by measuring fractions of haemoglobin A and haemoglobin F with high performance liquid chromatography (HPLC) or electrophoresis. In addition, DNA analysis is required to detect an α or β globin chain mutation (Peters 2012). It is estimated that between two and five per cent of the world's population are carriers and this is more prevalent in the Mediterranean and Southern Asian populations (Modell 2001). Morbidity is related to severe anaemia and an affected child will require lifelong blood transfusions. Multiple blood transfusions may eventually result in iron overload and potentially cause heart failure, infection, hypogonadism, infertility, diabetes mellitus, and hypothyroidism. Affected individuals may die prematurely, unless given optimal medical management. In individuals with thalassaemia and their families or care givers, psychosocial problems have also been reported, for example stigmatisation, isolation, family adjustment, coping with school and education, and social interaction (Gharaibeh 2009; Ratip 1996; Telfer 2005).

Sickle cell disease

Sickle cell disease is caused by a mutation in the haemoglobin gene (β^S) which individuals inherit from both parents (Weatherall 1997). The WHO estimates that sickle cell disease affects 275,000 conceptions each year globally (Modell 2008; Yusuf 2011). Diagnosis is confirmed using HPLC or electrophoresis with the detection of haemoglobin S and C fraction. It affects mainly individuals of African origin, but is also found in Indian and some Mediterranean populations. The reported prevalence of carrier frequency ranges from one to 40 per cent, depending on the population group. The condition causes the red blood cells to have a sickle shape which results in premature haemolysis, and can lead to life-threatening acute and chronic vaso-occlusion, including renal and cardiovascular complications. Individuals with this condition are also susceptible to serious septicaemia. Like thalassaemia, individuals and their families are also confronted with psychosocial challenges which include the disruption of school and work, social isolation and loneliness, stigmatisation, bullying, and rejection by peers (Barbarin 1999).

Cystic fibrosis

Cystic fibrosis is caused by a mutation in the gene cystic fibrosis transmembrane conductance regulator (CFTR); more than 1500 CFTR mutations have now been identified. Diagnosis of cystic fibrosis is indicated by phenotypic features (chronic sino-pulmonary disease, gastrointestinal and nutritional abnormalities, obstructive azoospermia and salt-loss syndromes), a family history of cystic fibrosis or a positive newborn screening test, together with laboratory evidence of a CFTR abnormality. Abnormalities in the CFTR can be identified by elevated sweat chloride concentrations (sweat test), identification of two CFTR mutations, or *in vivo* demonstration of characteristic abnormalities in ion transport across the nasal epithelium. Carriers are confirmed by identification of a CFTR mutation from the blood or saliva (CDC 2004).

Cystic fibrosis is most common among people of European descent with a carrier frequency of 1 in 25 (Murray 1999). This condition is commonly associated with recurrent pulmonary infections, which potentially lead to bronchiectasis and atelectasis, and also pancreatic exocrine insufficiency. There is currently no cure for the disease, with treatment mainly aimed at improving a person's quality of life. The need for emotional and social adjustment is a significant psychosocial consequence for people with cystic fibrosis (Bregnballe 2007; Glasscoe 2008). In addition, poor adherence to treatment has also been reported due to the burden of treatment and the long-term management of the condition (Abbot 1996).

Tay-Sachs disease

Tay-Sachs disease is caused by a genetic mutation in the α chains of the hexosaminidase A (Hex A) isozyme in the gangliosides in nerve cells of the brain (Bach 2001). The disease is diagnosed by measuring the activity of hexosaminidase A and further identification of a genetic mutation in Hex A (ACOG Committee Opinion 2005). It is most prevalent in the Ashkenazi Jewish and French Canadian populations, with a carrier frequency of around 1 in 30 (Petersen 1983; Palomaki 1995). The condition leads to a progressive deterioration of mental and physical abilities. Death usually occurs before five years of age. At present, there is no cure or available treatment.

Description of the intervention

Women and their partners can be assessed during the preconception period to identify if they are carriers of one of these four autosomal recessive conditions. These four conditions represent the most common autosomal recessive conditions globally. Cystic fibrosis is most common in Northern European populations; sickle cell disease and thalassaemia are most common non-Northern European populations, and Tay-Sachs disease is most common in individuals of Ashkenazi Jewish and French Canadian ancestry. Approaches to improve health outcomes and reproductive choice in couples who carry these genetic conditions should be generalizable

to other, but rarer, autosomal recessive conditions. In populations with high carrier rates or significant burden of affected individuals, or both, carrier screening may be offered during preconception to all women in some healthcare settings (PFASP England 2013). More commonly, women and their partners may be assessed on the need for carrier testing. This assessment would be based firstly on a review of the family history for any of the autosomal recessive conditions or their carrier status; and, secondly, on the ethnic origin of the woman and her partner (Dyson 2006). This assessment of ancestry will identify if the individual originates from an ethnic group with a greater probability of being a healthy carrier of any of the four autosomal recessive disorders; for example those with Ashkenazi Jewish ancestry are more likely to carry Tay-Sachs disease, whilst those of African descent may carry sickle cell trait. The benefits of recording family history as one of the components of preconception health checks have been reported in previous observational community-based studies for a broad range of genetic conditions in both the United Kingdom (Rose 1999) and Hungary (Czeizel 2012).

Overall, previous interventions have involved genetic carrier testing or screening (with or without educational support and genetic counselling) or both. There is often confusion between the terms genetic carrier testing and screening (Nuffield Council on Bioethics 1993). Genetic carrier testing refers to the testing of individuals to determine the presence or absence of the carrier status (Human Genetics Commission 2011). This testing could, for example, be in the context of a family history of the autosomal recessive condition or relevant ethnicity. On the other hand, genetic carrier screening involves offering or testing the whole population group irrespective of individual risk (Castellani 2010; Human Genetics Commission 2011). Both genetic carrier testing and screening involves the analysis of blood, tissue or bodily fluid samples.

With regards to the actual genetic carrier tests, currently either HPLC or electrophoresis is used to detect haemoglobin variants and to confirm carrier status for thalassaemia and sickle cell disease (NHS Screening Programme 2013). Carrier status for cystic fibrosis is confirmed by analysing the mutations in the gene CFTR, using DNA commonly obtained from white blood cells, mouthwashes and buccal swabs (Murray 1999). Confirmation of Tay-Sachs disease carrier status comprises of molecular analysis to detect genetic mutations in the α chains of the hexosaminidase A (Hex A) isozyme (ACOG Committee Opinion 2005). To improve detection rate, this should be combined with biochemical tests (ACOG Committee Opinion 2005).

For each condition, as well as confirmed carrier status identified by genetic carrier tests, there are other laboratory investigations that could indicate a probable carrier state. A microcytic or hypochromic blood picture, or both, without anaemia suggests a probable thalassaemia carrier, whilst a probable sickle cell carrier is indicated by a positive sickle solubility test. Elevated sodium chloride levels in sweat can indicate a probable cystic fibrosis carrier

state.

At present, there is no formal or standard recommendation that fully addresses preconception genetic risk assessment (NHS Screening Programme 2013). There is variability in how preconception genetic risk assessment is offered across countries. For example, in Iran, screening for haemoglobinopathies is offered in pre-marital clinics (Samavat 2004), whereas in the United Kingdom, screening for any reproductive genetic disorder may be offered opportunistically in a range of settings such as family planning clinics (Watson 1999). Similarly, in current clinical practice, preconception risk assessment is not offered systematically, but most commonly offered opportunistically, for example when the issue is brought up by the couple (Heyes 2004).

How the intervention might work

In the specified autosomal recessive disorders (thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease), preconception genetic risk assessment ensures at-risk couples, in which both the women and her partner are carriers of the specified conditions, are aware that they have a one in four chance of an affected child prior to pregnancy, enabling them to make fully informed reproductive choices (Christie 2009; Czeizel 2012; Lena-Russo 2002; Massie 2009; Mitchell 1996). This offers the at-risk couples the opportunity to consider the full range of reproductive options (Borry 2011); for instance, couples may choose to have *in vitro* fertilisation (IVF) with pre-implantation genetic diagnosis, use donor gametes, adopt a child or remain childless (Human Genetics Commission 2011; Jones 2002; Wille 2004). These options are not available to couples who are only made aware of their reproductive genetic risk during the pregnancy. Of equal importance, if couples who have already been informed of their risk, decide to carry on with pregnancy they may consider and be offered prenatal diagnosis earlier in pregnancy. This enables the option of termination in early gestation, or can enhance preparation for foetal and maternal well-being throughout pregnancy, preparation following the birth of an infant, and postnatal support. (Wille 2004). If the carrier testing is implemented in the antenatal period, all of these decisions are delayed (Qureshi 2004). With regards to family history assessment, participants have acknowledged that this intervention enables pregnancy planning (Rose 1999) and early identification of couples at reproductive genetic risk (Czeizel 2012).

At a societal level, preconception carrier state identification has reduced the rate of affected births (Angastiniotis 1998; Samavat 2004). Although, it is estimated that preconception screening programmes worldwide have caused a small decrease in affected births for haemoglobin disorders from 2.7 per 1000 conceptions to 2.55 per 1000 conceptions over a five-year period from 1998 to 2003, more data and across all common autosomal recessive conditions need to be explored (Modell 2008). Similarly, early observational studies involving genetic carrier screening programmes for Tay-Sachs disease and thalassaemia in Canada and France carried out

in high school students were associated with increased rate of early prenatal diagnosis and termination of affected pregnancies (Lena-Russo 2002; Mitchell 1996; Zeesman 1984). In Cyprus and Iran, the incidence of thalassaemia has fallen with the introduction of mandatory pre-marital genetic carrier screening programmes (Alswaidi 2009; Angastiniotis 1998; Samavat 2004). In Hungary, preconception screening has resulted in improved identification of carrier couples and access to genetic counselling services (Czeizel 2012). However, such observational studies are subject to bias.

Why it is important to do this review

While a number of observational studies have reported the potential benefits of preconception risk assessment for genetic conditions in general (Czeizel 2012), and specifically for cystic fibrosis (Christie 2009; Massie 2009), haemoglobinopathies (Cao 1996) and Tay-Sachs disease (Mitchell 1996), as with other programmes for genetic testing or screening, this has potential adverse effects. Genetic assessment for reproductive risk has been linked to psychological distress such as anxiety; however, the raised anxiety was a transient phenomenon (Archibald 2011; Bekker 1994). Further, it has been reported that carrier status may be associated with a poor perception of health (Henneman 2001) and may have an impact on the carrier's relationships with their partner (Fanos 1995). Social impacts such as stigmatisation and discrimination have been reported with mandatory carrier screening (Bonham 2010; Kenen 1978; Whitten 1973). Despite these reported adverse effects, there are numerous psychological benefits including the opportunity for informed decision-making and reproductive autonomy in prospective parents (Anido 2005; Archibald 2011; Lewis 2011).

With regards to the economic implications, as for other programmes for genetic testing and screening, there is an opportunity cost for redistributing resources from medical care to preconception risk assessment (WHO 1968). Several economic appraisals of haemoglobinopathies screening in the antenatal and neonatal settings have indicated that these strategies are cost-effective (Davies 2000; Zeuner 1999). A recent review of existing screening programmes in Australia has shown that targeted preconception screening in certain ethnic groups demonstrates both clinical and cost-effectiveness (Lew 2014).

At a policy level, preconception genetic risk assessment has been recommended in clinical practice in the Netherlands, the United States of America and the United Kingdom (ACOG Committee Opinion 2009; Health Council of Netherlands 2007; Human Genetics Commission 2011). However, a comprehensive review of the current evidence still needs to be undertaken to directly inform healthcare practice.

This review will explore if robust trial evidence exists on the effect of preconception genetic risk assessment for genetic disorders, particularly before its widespread routine implementation in current healthcare settings.

OBJECTIVES

The purpose of this review is to assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease in healthcare settings, when compared to usual care.

METHODS

Criteria for considering studies for this review

Types of studies

We planned for this review to include all relevant randomised controlled trials (RCTs) and quasi-randomised controlled trials (quasi-RCTs).

Types of participants

Women and their partners of reproductive age (aged 16 to 50 years old) who are carriers for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease, accessing any healthcare services which include hospitals and community-based healthcare settings. Community-based healthcare settings include family or general practices, community health centres, community health services, community or outpatient clinics and ambulatory care services. Settings outside of healthcare do not directly inform healthcare practice, and thus will be excluded as being outside the scope of this review. If trials contain both eligible and ineligible participants, they will be included if data on eligible participants can be extracted.

Types of interventions

We planned to assess the effects of systematic preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease, in any healthcare setting. We define systematic preconception genetic risk assessment as a package of risk assessment including one or more of these components:

- family history assessment;
- assessment of ethnicity background;
- genetic carrier testing;
- genetic carrier screening.

Risk assessment can be offered at anytime prior to conception. We planned to compare systematic preconception genetic risk assessment with standard care. We define standard care as where people receive usual or alternative care in any healthcare setting, that does not involve a specific systematic approach to preconception genetic risk assessment.

Types of outcome measures

The listed outcomes do not form part of the eligibility criteria for the included trials.

Primary outcomes

1. Reproductive outcomes in women and their partners who are carriers of thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease identified during or after pregnancy
    i)   number of infants born with genetic conditions
    ii) number of infants born with congenital anomalies
    iii) number of infants born with low birth weight
    iv) number of infants born prematurely
2. Decisions about future conception and pregnancy in women and their partners who are carriers for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease
    i)   number of women or couples who would make use of prenatal diagnosis
    ii) number of women or couples who would make use of prenatal diagnosis and consider termination of pregnancy if the child is affected
    iii) number of women or couples who would consider pre-implantation genetic diagnosis and *in vitro* fertilization
    iv) number of women or couples who would conceive using donated gametes
    v)   number of women or couples who would consider adoption
    vi) number of women or couples who would refrain from having any children

Secondary outcomes

1. During pregnancy following intervention
    i) gestational date of prenatal diagnosis in at-risk women
    ii) gestational date of prenatal counselling in at-risk women or couples
2. Self-reported measures (short-term change from baseline)
    i)   any objective measures of health-related quality of life resulting from preconception genetic risk assessment, using validated tools such as Short Form Health Survey 36 (SF36) and Health Questionnaire EQ-5D
    ii) any objective measures of quantifying psychological or social outcomes or both resulting from preconception genetic risk assessment using validated tools such as Spielberger State-Trait Anxiety Inventory (STAI), Perceived Stress Questionnaire (PSQ)
    iii) knowledge (any measures of the women's or couples' or both, knowledge of reproductive genetic risk associated with carrier status for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease using validated self-reported questionnaire)
    iv) satisfaction (any measures of the women's or couples' or both, satisfaction with the intervention using validated self-reported questionnaire)

3. Cost of the intervention (including follow-up visits and tests)

Search methods for identification of studies

We did not apply language restrictions in the electronic searches. If we identify potentially eligible non-English language trials in future searches, we will source a person who can read the language in order to assess these trials for possible inclusion and data extraction.

Electronic searches

We sought trials from the relevant Cystic Fibrosis and Genetic Disorders Group's Trials Registers using the terms: (carrier* OR trait OR risk assessment OR Tay-Sachs)) AND ((cystic fibrosis OR haemoglobinopathies OR Tay-Sachs). For full details of all searching activities for the registers, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group Module.

Date of latest search: 25 June 2015.

In addition, we searched all relevant trials from the following databases:

1. Ovid MEDLINE (1970 until 10 December 2014);
2. Ovid Embase ((1974 until 10 December 2014);
3. CINAHL (1970 until 10 December 2014);
4. Ovid PsycINFO (1970 until 10 December 2014).

The search strategies are available in the appendices (Appendix 2; Appendix 3; Appendix 4; Appendix 5). Start dates for database searches are set to when carrier screening or testing was first available. Based on WHO reports, earliest carrier status assessment was introduced for Tay-Sachs disease and haemoglobinopathies from the early 1970s (Angastiniotis 1995; Kaback 2000). We searched for relevant trials in the databases from 1970 or from when the date of the database was first available if after 1970.

We searched the following clinical trial databases for ongoing and unpublished trials:

- National Institutes of Health database;
- Clinical Trials Search Portal of the World Health Organization;
- Current Controlled Trials in the metaRegister of controlled clinical trials

Searching other resources

We planned to examine the reference lists of eligible published trials to identify further relevant trials. We hand searched the key journals *European Journal of Human Genetics, Genetics in Medicine* and the *Journal of Community Genetics* from 1998 to 06 January 2014. We complemented the search by contacting subject experts or centres in the field to request any unpublished or other published trials that we may not have identified.

Data collection and analysis

Selection of studies

We saved the results of the searches in the Endnote reference managing software (EndNote X3). Two review authors (one content expert and one methodologist) independently screened the citations and article abstracts of every retrieved record. We would have resolved any disagreements on eligibility by discussion and if doubt remained, we would have acquired the relevant full article(s) for further inspection. Two review authors independently screened all full text articles of the eligible trials. We aimed to resolve any disagreement by discussion. If required, we would have consulted a third review author. If necessary, we planned to contact the authors of the articles for further information and clarification of trials. We have reported reasons for excluding trials and provided a PRISMA flowchart (Figure 1).

Figure 1. Study flow diagram

We did not identify any trials for inclusion in this version of the review. However, if we identify any trials for future updates of the review, we plan to undertake the following.

Data extraction and management

Two review authors will independently extract data from each included trial using an agreed data extraction form. We will collect data on trial population characteristics (including sample size, participants' ethnic or cultural characteristics, geographic locations), intervention characteristics (including process and duration of intervention) and primary and secondary outcome measures of interest. We plan to report short-term outcomes post intervention up to six months. We plan to report long-term outcomes post intervention from six months up to 12 months, and then annually thereafter.

We will settle any disagreements about the data extracted through discussion by the two review authors, and if necessary by arbitration with a third author. We will enter all the data into the Review Manager software (RevMan 2014).

Assessment of risk of bias in included studies

We will construct a risk of bias table for each trial as outlined in chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

Two review authors will independently assess and record the following six domains in the risk of bias table:

1. random sequence generation;
2. allocation sequence concealment;
3. blinding of participants, trial personnel, outcome assessors;
4. incomplete outcome data;
5. selective outcome reporting;
6. other sources of bias.

We will judge the methods used in the trials for each domain as having either a low, high or unclear risk of bias. Two review authors will aim to resolve any disagreements in the judgement of the domains through discussion. If no agreement can be reached, then they will consult a third author and aim to resolve the disagreement by consensus.

We will record the information in the 'Risk of bias' tables in Review Manager (RevMan 2014). We aim to resolve any disagreement by consensus or arbitration by a third author. We will use the results of the risk of bias assessment to provide an evaluation of the overall risk of bias of the included trials based on the approach outlined in the chapter 8 (Table 8.7a) of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

Measures of treatment effect

We will extract all the main results of the included trials as mentioned below. We will contact relevant authors of the original reports for data or any missing relevant information or when clarification is needed. We will settle any disagreements about the data extracted through discussion and if necessary by arbitration by a third author. We will enter all the data into the Review Manager software (RevMan 2014).

Continuous data

For scale-derived data, we will include continuous data from rating scales only if the measuring instrument has been validated. We will include endpoint data and only use change data if the former are not available. For continuous outcomes we will record mean, standard deviation (SD) and number of participants for each group and report effect size using the mean difference (MD) for the same units of measurement or the standardised mean difference (SMD) when different scales are used to evaluate the same outcome, with 95% confidence intervals (CI). The MD measures the absolute difference between the means in two groups, whereas the SMD is the MD relative to variability observed in that trial.

Dichotomous data

We will report dichotomous data using the risk ratio (RR) and the corresponding 95% CIs.

Unit of analysis issues

We anticipate cluster-randomised designs to be used in the included trials; for example, groups of patients of a single doctor or practice. If available, we will extract the direct estimate of the effect (RR with CI) that accounts for a cluster design. We will contact the primary authors of the included trials to obtain the intra-cluster correlation coefficient (ICC) which will describe the relative variability within and between clusters, to adjust for clustering effect (Donner 1980). We will meta-analyse the appropriate analyses of cluster randomised trials using the generic inverse variance method. Alternatively, we will estimate an ICC to describe the relative variability within and between clusters (Donner 1980). An ICC usually derives from the trial or from other sources (ICC from a similar trial in an existing database) (Ukoumunne 1999). If the ICC is derived from other sources, we will report this and conduct a sensitivity analysis. If the trials were analysed as if the randomisation was performed on the individuals rather than the clusters, we will re-calculate the correct analysis if we are able to extract the following information: the number of clusters randomised to each intervention group; the mean size of each cluster; and the outcome data ignoring the cluster design for the total number of individuals.

If we identify more than one intervention group of interest in a trial, we will analyse the effect of the additional intervention group using pair-wise comparisons. If the additional intervention group is irrelevant, we will not reproduce the data.

Dealing with missing data

Whenever possible, we will contact the original investigators and the authors of the included trials to request any missing data. If this is unsuccessful we will deal with missing data as mentioned below.

Overall loss of credibility

We will choose that, if for any particular outcome there is a high risk bias for missing data according to the risk of bias assessment, we will not use these data in the analyses and will present the results in the form of a narrative synthesis.

Continuous data

If SDs are not reported or available, we will first look for statistics that allow the calculation of the SD (for example, the CI and the standard error (SE) of group means, as well as P values and T values for the differences in means). If this is not possible, we will consider imputing SDs of other included trials. We will examine the consequences of imputations in a sensitivity analysis.

Assessment of heterogeneity

Clinical heterogeneity

We will consider clinical heterogeneity which can result from differences between trials in characteristics of the populations, interventions and outcomes. We will fully discuss the influence of clinical heterogeneity on the observed effects.

Methodological heterogeneity

We will assess for methodological heterogeneity, which can result from differences in characteristics of the trial designs. We will fully discuss the influence of methodological heterogeneity on the observed effects.

Statistical heterogeneity

We plan to examine graphs or summary tables of the trials to investigate the possibility of statistical heterogeneity. We plan to consider the I^2 statistic which estimates the proportion of variability in effect estimates that is due to heterogeneity (Higgins 2002). We will determine the level of heterogeneity by the following reference ranges: low 0% to 40%; moderate 41% to 75%; and high 76% to 100%. We also plan to use the Chi^2 statistic and if the P value is less than 0.10 it will be considered an indication of heterogeneity. If there is a high level of heterogeneity between trials, it may not be appropriate to conduct a meta-analysis, thus we will present results in a qualitative analysis. These trials will be entered into RevMan and presented on a forest plot with their individual effect sizes, but with no combined effect to give an overall picture of evidence (RevMan 2014).

Assessment of reporting biases

If the review includes more than 10 trials, we will create a funnel plot to investigate the possibility of small trial effects (a tendency for the intervention effects estimated in smaller trials to differ from those estimated in larger trials) (Sterne 2011).

Data synthesis

We will summarise all trials using narrative synthesis methods. This will involve the use of narrative text and tables to summarise data, consider outcomes in the light of differences in trial designs and address potential sources of bias for each of the trials being reviewed. We will group trials according to types of genetic conditions, and then organise them in terms of intervention and outcomes. We will summarise the results of the trials, including the range and size of any reported associations and important trial characteristics. We will also include a detailed commentary on the major methodological problems or biases affecting the trials, together with a description of how these may have affected the individual trial results.

We will use a random-effects model to conduct the meta-analysis due to anticipated differences between trial location and population. If there is substantial variation in results, particularly if there is inconsistency in the direction of effect, we will not perform a meta-analysis.

Subgroup analysis and investigation of heterogeneity

The authors will perform subgroup analyses where sufficient data are available. In the subgroup analyses, the authors will analyse the data in pre-specified subgroups of trials that share characteristics of interest, to see whether the intervention effect remains consistent or whether it varies for particular characteristics of trials. For this review, the authors aim to compare the effects of interventions on outcome measures in the following groups by:

- healthcare setting (primary, secondary, tertiary care or other);
- intensity of the intervention (number or duration of intervention sessions);
- nature of carrier status testing (confirmed genetic carrier status compared to probable carrier status);
- type of condition.

Sensitivity analysis

If there is a spread of bias across the trials, we will provide two estimates of the intervention effect; firstly for all included trials, and secondly only including trials with an overall assessment of a low risk of bias.

R E S U L T S

Description of studies

Results of the search

Database searching identified 4207 records. After screening 2695 unique records, 22 full-text articles describing 14 unique trials were retrieved for further analysis. No RCTs were found that were eligible for inclusion in the review. A flow diagram illustrates the search flow process (Figure 1).

Included studies

No RCTs were found to be eligible for inclusion in the review.

Excluded studies

Ten studies were excluded due to non-RCT study designs (Alhamdan 2007; Bekker 1993; Childs 1976; Clayton 1996; Hegwer 2006; Henneman 2001; Honnor 2000; Payne 1997; Tambor 1994; Watson 1991), while four RCTs were excluded because the intervention was not preconception genetic carrier testing or genetic carrier screening (Castellani 2011; Cheuvront 1998; Fisher 1981; Wilkie 2013). The table Characteristics of excluded studies summarises the study details and reasons for exclusions.

Risk of bias in included studies

No trials were included in this review.

Effects of interventions

No trials were eligible for inclusion in this review.

D I S C U S S I O N

Summary of main results

Identifying those couples before pregnancy, who have a confirmed genetic carrier status for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease may provide the opportunity for individuals or couples to make fully informed reproductive choices such as avoiding pregnancy, pre-implantation diagnosis, *in vitro* fertilisation, arranging early prenatal diagnosis, or consideration of adoption. However, there is currently no evidence from randomised controlled trials (RCTs) for the impact of genetic risk assessment for these conditions in non-pregnant women on pregnancy outcomes, informed reproductive choices or psychological adverse effects.

Overall completeness and applicability of evidence

To date, in many countries, reproductive genetic risk assessment for autosomal recessive disorders has focused on the antenatal period and carrier status that has emerged as an incidental finding in neonatal screening. In the antenatal period, carrier status is identified either through formal screening programmes, or opportunistically during antenatal follow up in women at increased risk based on ancestry. During the antenatal period, if both parents are found to be carriers of the genes (at-risk couples), prenatal diagnostic tests, such amniocentesis, may only be available either late in the first trimester or in the second trimester of pregnancy, which leaves the couple only a short period of time to make limited and difficult choices about termination or continuation of the pregnancy. This limits reproductive choices, with the potential of increased psychological distress in at-risk couples (Modell 1980a; Modell 1980b). The incidental finding of the carrier state during neonatal screening for the specific disorders has highlighted concerns from at-risk couples about the failure to offer this information prior to pregnancy (Locock 2008).

The evidence supporting genetic risk assessment before pregnancy has largely been from a series of observational studies (Alhamdan 2007; Bekker 1993; Childs 1976; Clayton 1996; Hegwer 2006; Henneman 2001; Honnor 2000; Payne 1997; Tambor 1994; Watson 1991). The majority of the observational studies have used before and after intervention designs (Bekker 1993; Clayton 1996; Hegwer 2006; Henneman 2001; Honnor 2000; Payne 1997; Tambor 1994; Watson 1991), while two studies utilised cross-sectional designs (Alhamdan 2007; Childs 1976). Four RCTs were also identified (Castellani 2011; Cheuvront 1998; Fisher 1981; Wilkie 2013). However, the intervention in these studies was not preconception genetic risk assessment. Only a few studies have assessed reproductive intentions (Cheuvront 1998; Henneman 2001; Watson 1991), whilst no studies have assessed actual reproductive outcomes. The limited duration of follow up in these studies would make assessment of latter outcomes unrealistic. All of the above studies have assessed psychological, attitudes, or knowledge outcomes, but there was some heterogeneity in these outcomes between and within studies. Further, none of the outcome

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)   11

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

measures for knowledge had used validated instruments. Although study participants recognised the importance of identifying genetic carrier states before pregnancy, different attitudes towards genetic testing were elicited and reproductive intentions varied following positive test results. In the Netherlands, study participants would consider prenatal diagnosis and abortion if an affected foetus is identified (Henneman 2001). In contrast, in the US state of Tennessee in a study of cystic fibrosis screening, reproductive intentions were limited by cultural and socio-political factors, such as, insurability, being labelled as 'at risk', a lack of understanding, and religious beliefs about abortion (Clayton 1996). In addition, barriers to implementation may be due to fears of stigma (Kenen 1978), legal discrimination (Lapham 1996), or religious restrictions on abortion (Fowzan 2001).

Despite the absence of robust and relevant RCT evidence, a number of international organisations have recommended offering preconception genetic risk assessment routinely at the population level (ACOG Committee Opinion 2005; ACOG Committee Opinion 2009; Health Council of Netherlands 2007; Human Genetics Commission 2011; Johnson 2006). In the United States of America, the recommendations to improve preconception health care were developed through collaborative efforts of the Centres for Disease Control and Prevention (CDC), March of Dimes and the American College of Obstetrics and Gynaecology (ACOG) (ACOG Committee Opinion 2005; Johnson 2006). For instance, the ACOG has recommended in couples planning pregnancy identify if either member of the couple are of Eastern European (Ashkenazi) Jewish ancestry or have a family history of relevant recessive genetic diseases (such as Tay-Sachs disease and Cystic Fibrosis), and such couples should be offered carrier screening before conception or early in pregnancy (ACOG Committee Opinion 2009).

Similarly the Health Council of Netherlands has recognised the seriousness of these conditions and high prevalence in local population groups, advocating preconception genetic risk assessment for cystic fibrosis, sickle cell and thalassaemia (Health Council of Netherlands 2007). However, the paucity of high quality studies limits the justification for national implementation.

The WHO's Regional Office of Eastern Mediterranean recommend preconception genetic risk assessment for sickle cell and thalassaemia ideally before marriage, taking account of the socio-cultural issues in the region, in particular religious reservations towards termination of pregnancy (Alwan 1997). Since the 1970s, the Cyprus Thalassaemia Control Programme has been at the forefront of premarital genetic screening and this has contributed to a fall in the prevalence of thalassaemia in the country (Angastiniotis 1981). This universal premarital approach to thalassaemia carrier screening has also been adopted by Sardinia, Italy (Cao 1996) and Greece (Loukopoulos 1996).

In line with international policy recommendations, the UK Human Genetics Commission has recognised that since antenatal screening is currently already offered for genetic conditions such as sickle cell disease and thalassaemia, there are no ethical, legal or social issues with regards to the implementation of a preconception screening programme which would provide the advantage of improving reproductive choices (Human Genetics Commission 2011).

In South East Asia, the Family Planning Association of Hong Kong has recognised the benefits of preconception screening of genetic risk due to the high prevalence of thalassaemia carriers, accounting for up to eight per cent of the local population (Lau 1997).

In the absence of high quality randomised controlled trials of preconception genetic risk assessment, as demonstrated in this systematic review, international policy makers must base recommendations on observational studies and consensus agreements.

Quality of the evidence

It has been suggested that the optimum evidence to evaluate the reproductive and psychological outcomes as a result of preconception screening, compared to standard practice, is a systematic review of RCTs, or a high quality RCT with a large enough sample size to ensure the control of potential confounding factors (National Screening Committee 2003). Such trials address methodological issues that are particularly associated with screening interventions such as ascertainment bias due to non-randomisation, with individuals joining screening programmes tending to have healthier lifestyles and better adherence to interventions (Smith 2003). In addition, none of the excluded studies identified in the searches for this review have evaluated reproductive outcomes. This is possibly related to the limited duration of follow up in these studies. Although preconception genetic carrier tests and screening have been shown to be to highly accurate and efficient in determining carrier status (Bach 2001; CDC 2004; Peters 2012; Weatherall 1997), the effectiveness of such interventions is ultimately measured by their ability to reduce morbidity and mortality of the diseases. Therefore, reproductive outcomes are essential to addressing this question.

Since this systematic review shows that there is a complete lack of RCTs in the field of preconception genetic risk assessment for autosomal recessive conditions, healthcare providers need to assess whether the information provided in published policy recommendations and non-randomised studies is relevant to inform their preconception screening practice. Furthermore, healthcare providers have to balance the benefits of increasing reproductive choice against the potential psychological adverse effects from preconception genetic risk assessment, whilst taking into account the legal and socio-cultural context of their healthcare setting and patient population.

Potential biases in the review process

The review authors have attempted to limit the bias in the review process through multiple authors and non-author contributors who independently searched for trials, screened titles and abstracts, selected full-text articles and extracted data. Any disagreements were resolved by group discussion and consensus, and therefore it was unlikely that trials have been incorrectly excluded. Although all clinical trials should be registered, there is always the potential of publication bias. However, attempts have been made to minimise publication bias through searching the grey literature and contacting key experts in the field.

Agreements and disagreements with other studies or reviews

This is the only systematic review looking at preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease and there were no randomised controlled trials eligible for inclusion, and therefore no comparisons could be made to other reviews or studies.

A U T H O R S ' C O N C L U S I O N S

Implications for practice

No RCTs of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were found for inclusion in this review. Therefore, the research evidence on which to base clinical decisions is limited to non-randomised studies, which have largely formed the basis for current policy recommendations.

We have not identified any relevant trials up to most current search date 10 December 2014.

Implications for research

Previous observational studies and RCTs on preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease have been limited by duration of follow up and to assessment of psychological or knowledge outcomes. Adequately-powered RCTs assessing reproductive outcomes (number of affected children born with genetic conditions) and reproductive decision outcomes on future conception (termination, *in vitro* fertilisation, use of donor gametes, adoption, or refraining from having children) are needed to better inform recommendations for clinical practice. Any self-reported secondary outcome measures need to use validated instruments. These trials will require longer durations of follow up than previous studies, starting from pre-pregnancy and lasting into the post-natal period. In the future, rather than offering genetic testing for specific autosomal-recessive conditions, genomic technology, such as pan-ethnic massively parallel sequencing (Bell 2011), may be adopted in which a panel of genetic conditions is identified. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic risk assessment.

A C K N O W L E D G E M E N T S

R E F E R E N C E S

References to studies excluded from this review

Alhamdan 2007 *{published data only}*
Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. *Genetics in Medicine* 2007;**9**(6):372–7.

Bekker 1993 *{published data only}*
Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T. Uptake of cystic fibrosis testing in primary care: supply push or demand pull?. *British Medical Journal* 1993;**306**(6892):1584–6.

Castellani 2011 *{published data only}*
Castellani C, Perobelli S, Bianchi V, Seia M, Melotti P, Zanolla L, et al. An interactive computer program can effectively educate potential users of cystic fibrosis carrier tests. *American Journal of Medical Genetics* 2011;**155A**(4): 778–85.

Cheuvront 1998 *{published data only}*
Callanan NP, Cheuvront B, Sorenson JR. CF Carrier testing in a high risk population: Anxiety,risk perceptions, and reproductive plans of carrier by "non-carrier" couples. *Genetics in Medicine* 1999;**1**(7):323–7.
* Cheuvront B, Sorenson JR, Callanan NP, Stearns SC, DeVellis BM. Psychosocial and educational outcomes associated with home- and clinic-based pretest education and cystic fibrosis carrier testing among a population of at-risk relatives. *American Journal of Medical Genetics* 1998;**75** (5):461–8.

Childs 1976 *{published data only}*
* Childs B, Gordis L, Kaback MM, Kazazian HH. Tay-Sachs screening: motives for participating and knowledge of genetics and probability. *American Journal of Human Genetics* 1976;**28**(6):537–49.
Childs B, Gordis L, Kaback MM, Kazazian HH. Tay-

Sachs screening: social and psychological impact. *American Journal of Human Genetics* 1976;**28**(6):550–8.

Clayton 1996 *{published data only}*
Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW, Phillips JA. Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. *American Journal of Human Genetics* 1996;**58**(3):617–27.

Fisher 1981 *{published data only}*
* Fisher L, Rowley PT, Lipkin JR. Genetic counselling for beta-thalassemia trait following health screening in a health maintenance organization:comparison of programmed and conventional counselling. *American Journal of Human Genetics* 1981;**33**(6):987–94.
Rowley PT, Fisher L, Lipkin JR. Screening and genetic counselling for thalassemia trait in a population unselected for interest: effects on knowledge and mood. *American Journal of Human Genetics* 1979;**31**(6):718–30.
Rowley PT, Lipkin M Jr, Fisher L. Screening and genetic counselling for beta-thalassemia trait in a population unselected for interest: comparison of three counselling methods. *American Journal of Human Genetics* 1984;**36**(3): 677–89.

Hegwer 2006 *{published data only}*
Hegwer G, Fairley C, Charrow J, Ormond KE. Knowledge and attitudes toward a free education and Ashkenazi Jewish carrier testing program. *Journal of Genetic Counseling* 2006; **15**(1):61–70.

Henneman 2001 *{published data only}*
Henneman L, Bramsen I, van Kempen L, van Acker MB, Pals G, van der Horst HE, et al. Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. *Community Genetics* 2003;**6**(1):5–13.
* Henneman L, Bramsen I, van der Ploeg HM, Ader HJ, van der Horst HE, Gille JJP, et al. Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. *Journal of Medical Genetics* 2001;**38**(10):695–703.
Henneman L, Bramsen I, van der Ploeg, ten Kate, LP. Preconception cystic fibrosis carrier couple screening: impact, understanding, and satisfaction. *Genetic Testing* 2002;**6**(3):195–202.
Lakeman PL, Plass AMC, Henneman L, Bezemer PD, Cornel MC, ten Kate LP. Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands. *Genetics in Medicine* 2008;**10**(11):820–30.

Honnor 2000 *{published data only}*
Honnor M, Zubrick SR, Walpole I, Bower C, Goldblatt J. Population screening for cystic fibrosis in Western Australia: community response. *American Journal of Medical Genetics* 2000;**93**(3):198–204.

Payne 1997 *{published data only}*
Payne Y, Williams M, Cheadle J, Stott NC, Rowlands M, Shickle D, et al. Carrier screening for cystic fibrosis in

primary care: evaluation of a project in South Wales. The South Wales Cystic Fibrosis Carrier Screening Research Team. *Clinical Genetics* 1997;**51**(3):153–63.

Tambor 1994 *{published data only}*
Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. *American Journal of Human Genetics* 1994;**55**:626–37.

Watson 1991 *{published data only}*
* Watson EK, Mayall ES, Chapple J, Dalziel M, Harrington K, Williams C, et al. Screening for carriers of cystic fibrosis through primary health care services. *British Medical Journal* 1991;**303**(6801):504–7.
Watson EK, Mayall ES, Lamb J, Chapple J, Williamson R. Psychological and social consequences of community carrier screening programme for cystic fibrosis. *Lancet* 1992;**340** (8813):217–20.

Wilkie 2013 *{published data only}*
Wilkie DJ, Gallo AM, Yao Y, Molokie RE, Stahl C, Hershberger PE, et al. Reproductive health choices for young adults with sickle cell disease or trait: randomized controlled trial immediate posttest effects. *Nursing Research* 2013;**62**(5):352–61. [CENTRAL: 909226; CFGD Register: SC237 ; CRS: 5500050000000054; EMBASE: 23995469; PUBMED: 23995469]

Additional references

Abbot 1996
Abbot J, Dodd M, Webb AK. Health perceptions and treatment adherence in adults with cystic fibrosis. *Thorax* 1996;**51**(12):1233–8.

ACOG Committee Opinion 2005
American College of Obstetricians and Gynecologists. Screening for Tay-Sachs disease. *ACOG Committee Opinion No. 318. Obstetrics & Gynecology* 2005;**106**:893–4.

ACOG Committee Opinion 2009
American College of Obstetricians and Gynecologists. Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. ACOG Committee Opinion No. 442 Obstetrics & Gynecology 2009; Vol. 114:950–3.

Alswaidi 2009
Alswaidi FM, O'Brien SJ. Premarital screening programmes for haemoglobinopathies, HIV and hepatitis viruses: review and factors affecting their success. *Journal of Medical Screening* 2009;**16**(1):22–8.

Alwan 1997
Alwan A, Modell B. Community control of genetic and congenital disorders. *EMRO Technical Publication 24*. Alexandria: Eastern Mediterranean Regional Office: World Health Organization, 1997.

Angastiniotis 1981
Angastiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. *Lancet* 1981;**1**(8216):369–71.

Angastiniotis 1995
Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. *Bulletin of the World Health Organization* 1995;**73**(3):375–86.

Angastiniotis 1998
Angastiniotis M, Modell B. Global epidemiology of haemoglobin disorders. *Annals of the New York Academy of Sciences* 1998;**850**:251–69.

Anido 2005
Anido A, Carlson LM, Taft L, Sherman SL. Women's attitudes toward testing for fragile X carrier status: a qualitative analysis. *Journal of Genetic Counselling* 2005;**14**(4):295–306.

Archibald 2011
Archibald AD, Wilford BS. Population carrier screening: psychological impact. Encyclopedia of Life Sciences 2011. [DOI: 10.1002/9780470015902.a0005641.pub2

Bach 2001
Bach G, Tomczak J, Risch N, Ekstein J. Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. *American Journal of Medical Genetics* 2001;**99**(1):70–5.

Barbarin 1999
Barbarin OA, Whitten CF, Bond S, Conner-Warren R. The social and cultural of coping with sickle cell disease: the role of financial hardship in adjustment to sickle cell disease. *Journal of Black Psychology* 1999;**23**(3):294–315.

Bekker 1994
Bekker H, Denniss G, Modell M, Bobrow M, Marteau T. The impact of population based screening for carriers of cystic fibrosis. *Journal of Medical Genetics* 1994;**31**(5):364–8.

Bell 2011
Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, et al. Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing. *Science Translational Medicine* 2011;**3**(65):65ra4.

Bonham 2010
Bonham VL, Dover GJ, Brody LC. Screening student athletes for sickle cell trait: a social and clinical experiment. *New England Journal of Medicine* 2010;**363**(11):997–9.

Borry 2011
Borry P, Henneman L, Lakeman P, ten Kate LP, Cornel MC, Howard HC. Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. *Human Reproduction* 2011;**26**(5):972–7.

Boulton 1996
Boulton M, Cummings C, Williamson R. The views of general practitioners on community carrier screening for cystic fibrosis. *British Journal of General Practice* 1996;**46**(406):299–301.

Bregnballe 2007
Bregnballe V, Thastum M, Schiøtz PO. Psychosocial problems in children with cystic fibrosis. *Acta Paediatrica* 2007;**96**(1):58–61.

Cao 1996
Cao A, Rosatelli MC, Gallanello R. Control of beta-thalassaemia by carrier screening, genetic counselling, and prenatal diagnosis: the Sardinian experience. *Ciba Foundation Symposium* 1996;**197**:137–51.

Castellani 2010
Castellani C, Macek M Jr, Cassiman JJ, Duff A, Massie J, ten Kate LP, et al. Benchmarks for cystic fibrosis carrier screening: a European consensus document. *Journal of Cystic Fibrosis* 2010;**9**(3):165–78.

CDC 2004
Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, et al. Newborn screening for cystic fibrosis. Evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recommendations Report 2004; Vol. 53, issue RR–13:1–36.

Christie 2009
Christie LM, Ingret AJ, Turner GM. Outcomes of a cystic fibrosis carrier testing clinic for couples. *Medical Journal of Australia* 2009;**191**(9):499–501.

Czeizel 2012
Czeizel AE. Experience of the Hungarian Preconception Service between 1984 and 2010. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2012;**161**(1):18–25.

Davies 2000
Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. *Health Technology Assessment* 2000;**4**(3):1–99.

Donner 1980
Donner A, Koval JJ. The estimation of intraclass correlation in the analysis of family data. *Biometrics* 1980;**36**(1):19–25.

Dormandy 2008
Dormandy E, Gulliford MC, Reid EP, Brown K, Marteau TM. Delay between pregnancy confirmation and sickle cell and thalassaemia screening: a population-based cohort study. *British Journal of General Practice* 2008;**58**(548):154–9.

Dyson 2006
Dyson SM, Culley LA, Gill C, Hubbard S, Kennefick A, Morris P, et al. Ethnicity questions and antenatal screening for sickle cell/thalassaemia [EQUANS] in England: A randomized controlled trial of two questionnaires. *Ethnicity and Health* 2006;**11**(2):169–89.

EndNote X3 [Computer program]
Thomson Reuters. EndNote X3. Thomson Reuters, 2009.

Fanos 1995
Fanos JH, Johnson JP. Barriers to carrier testing for adult cystic fibrosis sibs: the importance of not knowing. *American Journal of Medical Genetics* 1995;**59**(1):85–91.

Fowzan 2001
Fowzan S, Alkuraya, Ramzi AK. Attitude of Saudi families affected with hemoglobinpathies towards prenatal

screening and abortion and the influence of religious ruling (Fatwa). *Prenatal Diagnosis* 2001;**21**(6):448–51.

Gharaibeh 2009

Gharaibeh H, Amarneh BH, Zamzam SZ. The psychological burden of patients with beta thalassemia major in Syria. *Pediatrics International* 2009;**51**(5):630–6.

Glasscoe 2008

Glasscoe CA, Quittner AL. Psychological interventions for people with cystic fibrosis and their families. *Cochrane Database of Systematic Reviews* 2008, Issue 3. [DOI: 10.1002/14651858.CD003148.pub2

Health Council of Netherlands 2007

Health Council of Netherlands. Preconception care: A good beginning. The Hague: Health Council of Netherlands 2007. [ISBN: 978–90–5549–678–5]

Heyes 2004

Heyes T, Long S, Mathers N. Preconception care. Practice and beliefs of primary care workers. *Family Practice* 2004; **21**(1):22–7.

Higgins 2002

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**(11):1539–58.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Human Genetics Commission 2011

Human Genetics Commission. Increasing options, informing choice: A report on preconception genetic testing and screening. Human Genetics Commission. UK, 2011.

Johnson 2006

Johnson K, Posner SF, Biermann J, Cordero JF, Atrash HK, Parker CS, et al. Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recommendation Report 2006; Vol. 55, issue RR–6:1–23.

Jones 2002

Jones SL, Fallon LA. Reproductive options for individuals at risk for transmission of a genetic disorder. *Journal of Obstetric, Gynecologic, & Neonatal Nursing* 2002;**31**(2): 193–9.

Kaback 2000

Kaback MM. Population-based genetic screening for reproductive counselling: the Tay-Sachs disease model. *European Journal of Pediatrics* 2000;**159**(3):192–5.

Kenen 1978

Kenen RH, Schmidt RM. Stigmatization of carrier status: social implications of heterozygote genetic screening

programs. *American Journal of Public Health* 1978;**68**(11): 1116–20.

Lapham 1996

Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. *Science* 1996;**274**(5287):621–4.

Lau 1997

Lau YL, Chan LC, Chan YY, Ha SY, Yeung CY, Waye JS, et al. Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong -- implications for population screening. *New England Journal of Medicine* 1997;**336**(18): 1298–301.

Lena-Russo 2002

Lena-Russo D, Badens C, Aubinaud M, Merono F, Paolasso C, Martini N, et al. Outcome of a school screening programme for carriers of haemoglobin disease. *Journal of Medical Screening* 2002;**9**(2):67–9.

Lew 2014

Lew RM, Burnett L, Proos AL, Barlow-Stewart K, Delatychi MB, Bankier A, et al. Ashkenazi Jewish population screening for Tay-Sachs disease: the international and Australian experience. *Journal of Paediatrics and Child Health* 2014;**51**(3):271–9.

Lewis 2011

Lewis C, Skirton H, Jones R. Reproductive empowerment: The main motivator and outcome of carrier testing. *Journal of Health Psychology* 2011;**17**(4):567–78.

Locock 2008

Locock L, Kai J. Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. *British Journal of General Practice* 2008;**58** (548):161–8.

Loukopoulos 1996

Loukopoulos D. Current status of thalassemia and the sickle cell syndromes in Greece. *Seminars in Hematology* 1996;**33** (1):76–86.

Massie 2009

Massie J, Petrou V, Forbes R, Curnow L, Ioannou L, Bankier A, et al. Population-based carrier screening for cystic fibrosis in Victoria: The first three years experience. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2009;**49** (5):484–9.

Mennie 1998

Mennie M, Campbell H, Liston WA, Brock DJ. Attitudes of general practitioners to screening for cystic fibrosis. *Journal of Medical Screening* 1998;**5**(1):11–5.

Mitchell 1996

Mitchell JJ, Capua A, Clow C. Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and β-Thalassemia disease carriers in high schools. *American Journal of Medical Genetics* 1996;**59**:793–8.

Modell 1980a

Modell B, Mouzouras M, Camba L, Ward RHT, Fairweather DVI. Population screening for carriers of recessively inherited disorders. *Lancet* 1980;**316**(8198):806.

Modell 1980b
Modell B, Ward RHT, Fairweather DVI. Effect of introducing antenatal diagnosis on reproductive behaviour of families at risk for thalassaemia major. *British Medical Journal* 1980;**280**(6228):1347–50.

Modell 2001
Modell B, Khan M, Darlison M, King A, Layton M, Old J, et al. A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. *Bulletin of the World Health Organization* 2001;**79**(11): 1006–13.

Modell 2008
Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. *Bulletin of the World Health Organization* 2008;**86**(6):480–7.

Murray 1999
Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J. Screening for cystic fibrosis. Health Technology Assessment 1999; Vol. 3, issue 8.

National Screening Committee 2003
UK National Screening Committee. Criteria for screening programmes. http://www.screening.nhs.uk/criteria (accessed 22 July 2014).

NHS Screening Programme 2013
NHS Sickle Cell & Thalassaemia Screening Programme. United Kingdom National Screening Programmes Information Strategy. http://sct.screening.nhs.uk (accessed 8 January 2013).

Nuffield Council on Bioethics 1993
Nuffield Council on Bioethics. Genetic screening: ethical issues. Nuffield Council on Bioethics. London, 1993. [ISBN: 0 9522701 0 2]

Palomaki 1995
Palomaki GE, William J, Haddow JE, Natowicz MR. Tay-Sachs disease in persons of French-Canadian heritage in northern New England. *American Journal of Medical Genetics* 1995;**56**(4):409–12.

Peters 2012
Peters M, Heijboer H, Smiers F, Giordano PC. Diagnosis and management of thalassaemia. *BMJ* 2012;**344**:e228.

Petersen 1983
Petersen GM, Rotter JI, Cantor RM, Field LL, Greenwald S, Lim JS, et al. The Tay-Sachs disease gene in North American Jewish populations: geographic variations and origin. *American Journal of Human Genetics* 1983;**35**(6): 1258–69.

PFASP England 2013
NHS Sickle Cell and Thalassaemia Screening Programme Centre. Policy Framework for Antenatal Screening Programme for England. http://sct.screening.nhs.uk/ cms.php?folder=2424 (accessed 2 September 2013).

Poppelaars 2004
Poppelaars FAM, Ader HJ, Cornel MC, Henneman L, Hermens RPMG, van der Wal G, et al. Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening. *Journal of Genetic Counseling* 2004;**13**(1): 31–44.

Qureshi 2004
Qureshi N, Modell B, Modell M. Raising the profile of genetics in primary care. *Nature Reviews Genetics* 2004;**5** (10):783–90.

Ratip 1996
Ratip S, Modell B. Psychological and sociological aspects of the thalassemias. *Seminars in Hematology* 1996;**33**(1): 53–65.

RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Rose 1999
Rose P. Humm E, Hey K, Jones L, Huson SM. Family history taking and genetic counselling in primary care. *Family Practice* 1999;**16**(1):78–83.

Samavat 2004
Samavat A, Modell B. Iranian national thalassaemia screening programme. *BMJ* 2004;**329**(7475):1134.

Shapira 2006
Shapira SK, Dolan S. Genetic risks to the mother and the infant: assessment, counselling, and management. *Maternal & Child Health Journal* 2006;**10**(5):143–6.

Smith 2003
Smith RA, Mettlin CJ, Eyre H. Methodologic issues in the evaluation of early detection programs. In: Kufe DW, Pollock RE, Weichselbaum RR editor(s). *Holland-Frei Cancer Medicine*. 6th Edition. Hamilton (ON): BC Decker, 2003.

Sterne 2011
Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group (editors). Chapter 10: Addressing reporting bias. In; Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Teeuw 2010
Teeuw ME, Henneman L, Bochdanovits Z, Heutink P, Kuik DJ, Corneland MC, et al. Do consanguineous parents of a child affected by an autosomal recessive disease have more DNA identical-by-descent than similarly-related parents with healthy offspring? Design of a case-control study. *BMC Medical Genetics* 2010;**11**:113.

Telfer 2005
Telfer P, Constantinidou G, Andreou P, Christou S, Modell B, Angastiniotis M. Quality of life in thalassemia. *Annals of the New York Academy of Sciences* 2005;**1054**(1):273–82.

Ukoumunne 1999
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based interventions in health and health care:

a systematic review. *Health Technology Assessment* 1999;**3**(5): iii–92.

Watson 1999

Watson EK, Shickle D, Qureshi N, Emery J, Austoker J. The 'new genetics' and primary care: GPs' view on their role and their educational needs. *Family Practice* 1999;**16** (4):420–5.

Weatherall 1997

Weatherall D. ABC of clinical haematology: the hereditary anaemias. *British Medical Journal* 1997;**314**(7079):492–6.

Whitten 1973

Whitten CF. Sickle-cell programming: an imperilled promise. *New England Journal of Medicine* 1973;**288**(6): 318–9.

WHO 1968

Wilson JMG, Jungner G. *Principles and practice of screening for disease*. Geneva: World Health Organization, 1968.

WHO 1999

WHO, World Alliance for the Prevention of Birth Defects. Services for the prevention and management of genetic disorders and birth defects in developing countries. WHO Human Genetics Programme; 1999 Jan 5-7; The Hague. Netherlands. 1999.

WHO 2000

World Health Organization. Genes and Human Disease. www.who.int/genomics/public/geneticdiseases/en/index2.html (accessed 8 May 2013), issue Publication no. 2007/19E. [ISBN: 978–90–5549–678–5]

Wille 2004

Wille MC, Weitz B, Kerper P, Frazier S. Advances in preconception genetic counselling. *Journal of Perinatal & Neonatal Nursing* 2004;**18**(1):28–40.

Yusuf 2011

Yusuf HR, Lloyd-Puryear MA, Grant AM, Parker CS, Creary MS, Atrash HK. Sickle cell disease: the need for a public health agenda. *American Journal of Preventive Medicine* 2011;**41**(6):376–83.

Zeesman 1984

Zeesman S, Clow CL, Cartier L, Scriver CR. A private view of heterozygosity: eight-year follow-up study on carriers of the Tay-Sachs gene detected by high school screening in Montreal. *American Journal of Medical Genetics* 1984;**18**(4): 769–78.

Zeuner 1999

Zeuner D, Ades AE, Karnon J. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. *Health Technology Assessment* 1999;**3** (11):1–186.

* *Indicates the major publication for the study*

CHARACTERISTICS OF STUDIES

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Alhamdan 2007	Participants: couples planning to marry and applying for marriage licence Intervention: premartial screening programme for sickle cell and beta-thalassemia Comparator: none Outcome: number confirmed sickle cell and beta thalassemia carriers, decision for marriage Design: observational, cross-sectional study Excluded due to non-RCT design
Bekker 1993	Participants: adults 18 - 45 years Intervention: genetic carrier testing for cystic fibrosis Comparator: none Outcome: anxiety Design: observational, before and after intervention study Excluded due to non-RCT study design
Castellani 2011	Participants: infertile couples undergoing cystic fibrosis screening as part of assisted reproduction process Intervention: genetic counselling via computer program Comparator: standard care genetic counselling session Outcome: knowledge Design: RCT Excluded because intervention was method of delivering genetic counselling and not preconception genetic carrier testing or screening compared to standard care
Cheuvront 1998	Participants: relatives of people with cystic fibrosis Intervention: home-based pretest education from pamphlet with genetic test Comparator: clinic based pretest education via genetic counselling with genetic test Outcome: anxiety, knowledge, satisfaction, reproductive intent Design: RCT Excluded because intervention was method of delivering genetic counselling and not preconception genetic carrier testing or screening compared to standard care
Childs 1976	Participants: carriers of Tay-Sachs disease identified prospectively or retrospectively during population screening Intervention: genetic carrier population screening Comparator: none Outcomes: knowledge, attitudes, anxiety, concerns, satisfaction Design: observational, cross-sectional Excluded due to non-RCT study design
Clayton 1996	Participants: non-pregnant adults visiting clinical and non-clinical sites Intervention: genetic carrier testing for cystic fibrosis Comparator: none Outcome: attitudes, beliefs Design: observational, before and after intervention design

(Continued)

	Excluded due to non-RCT study design
Fisher 1981	Participants: adults carriers of beta-thalassaemia 18 - 65 years in a HMO Intervention: genetic counselling through video Comparator: conventional counselling by trained physician Outcome: knowledge, sexual activity, mood change, behaviour, anxiety Design: RCT Excluded because intervention is not preconception genetic carrier testing or screening
Hegwer 2006	Participants: adults of Ashkenazi Jewish background in prenatal and preconception settings Intervention: genetic carrier screening and education programme for Tay-Sachs disease Comparator: none Outcome: knowledge, concern, attitudes, perceptions of genetic risk Design: observational, before and after intervention Excluded due to non-RCT study design
Henneman 2001	Participants: adults aged 20 - 35 years invited through Municipal Health Service or General Practitioner Intervention: genetic carrier screening for cystic fibrosis Comparator: none Outcome: knowledge, attitudes, understanding, satisfaction, psychological well-being, uptake, worry, reproductive intentions, sharing of information Design: observational, before and after intervention Excluded due to non-RCT study design
Honnor 2000	Participants: adults 18 - 50 years in a primary care setting Intervention: genetic carrier testing and counselling for cystic fibrosis Comparator: none Outcome: anxiety, knowledge Design: observational, before and after intervention Excluded due to non-RCT study design
Payne 1997	Participants: adults 16 - 45 years in one primary care practice in South Wales Intervention: genetic carrier testing for cystic fibrosis Comparator: none Outcome: knowledge, anxiety Design: observational, before and after intervention Excluded due to non-RCT study design
Tambor 1994	Participants: adults 18 - 44 years in a HMO Intervention: invitation offering cystic fibrosis carrier screening and information giving either by personal education on-site or by mailed brochure Comparator: none Outcome: attitudes, tolerance, utilization Design: observational, before and after intervention Excluded due to non-RCT study design
Watson 1991	Participants: adults 16 - 44 years from primary care practices and family planning clinics Intervention: genetic carrier testing for cystic fibrosis Comparator: none

	Outcome: anxiety, response to positive results, knowledge, reproductive intentions, behaviour Design: observational, before and after intervention Excluded due to non-RCT study design
Wilkie 2013	Participants: adults 18 - 35 years with sickle cell disease or sickle cell trait from clinics and community settings Intervention: web-based multimedia educational intervention Comparator: usual care information e-book Outcome: knowledge, reproductive intent and behaviour Design: randomised controlled trial Excluded because intervention was the delivery of education and not preconception genetic carrier testing or screening

HMO: health maintenance organisation
RCT: randomised controlled trial

DATA AND ANALYSES

This review has no analyses.

APPENDICES

Appendix 1. Glossary

Term	Explanation
Antenatal	A period during pregnancy and before birth of the child.
Ancestry	A person's ethnic origin or descent.
Atelectasis	A collapsed portion of the lung which does not contain air. This can be caused by excessive accumulations of mucous secretions, inhaled foreign bodies or bronchial cancers
Autosomal recessive genetic disorders	A genetic trait or disorder which appears only when an individual inherits a pair of chromosomes, each containing the gene for the trait. One chromosome of the pair comes from the father and the other from the mother. Autosomal recessive disorders can occur only if both parents are carriers of the trait
Bronchiectasis	Persistent and progressive dilation of bronchi (branches from the trachea which lead to the lungs) often as a consequence of inflammatory disease (lung infections)
Carrier (in genetics)	An individual who possesses one copy of a mutated allele that causes disease only when two copies are present (an autosomal recessive genetic disorders). A carrier is not affected by the disease, but two carriers can produce a child with the disease
Chronic vaso-occlusion	Blockage of arteries marked by long duration, by frequent recurrence over a long time, and often by slowly progressing deterioration; having a slow progressive course of indefinite duration
Cystic fibrosis transmembrane conductance regulator (CFTR)	A protein, involved in the movement of salt across cell membranes, which is lacking or does not function normally in people with cystic fibrosis
Diabetes mellitus	A pancreatic disorder that causes abnormal insulin production. This affects the body's ability to utilise sugar and other food substances and is usually treated by diet modification (restricted sugar intake) and use of insulin

DNA (Deoxyribonucleic acid)	The chemical coding for a gene. DNA determines the 'genetic message' within each cell, organ, and organism
Electrophoresis	A method of separating particles relative to a fluid under the influence of a spatially uniform electric field
Ethnicity	Common characteristics of people of a distinct national, racial or cultural group
Gangliosides	A group of glysolipid cells that are found in the brain.
Gene	The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein
Globin chains	Blood proteins found in red blood cells that are combined to make haemoglobin. They are α or β globin chains
Haemoglobin A	Normal adult haemoglobin.
Haemoglobin F	A kind of haemoglobin usually present during fetal (intrauterine) life, which has a different chemical structure from normal adult haemoglobin. After birth, the fetal haemoglobin in the red blood cells is gradually replaced by the adult type of haemoglobin, this process is usually complete during the first six months of life
Haemolysis	Breaking of the red cell membrane causing release of haemoglobin
Haemolytic anaemia	A condition where there are fewer red blood cells than average circulating in the blood stream due to breaking of the red cell membrane causing release of haemoglobin
Hexosaminidase A isozyme	A protein found in the nerve cells of the brain which does not function normally in people with Tay-Sachs disease
High performance liquid chromatography (HPLC)	A method that is used to separate a mixture of compounds to identify and quantify the individual components of the mixture
Hypothyroidism	Results from a deficiency of thyroid hormone, and is characterized by a decrease in basal metabolic rate and by tiredness, lethargy and sensitivity to cold
In vitro fertilization	A technique by which eggs are collected from a woman and fertilised with a man's sperm outside the body. Usually one or two resulting embryos are then transferred to the womb. If one or more of them implants successfully in the womb it results in a pregnancy

(Continued)

In vivo	Inside the living body.
Mutation	A change or alteration of the DNA sequence within a gene.
Nasal epithelium	The tissue that covers and lines the surface of the nose.
Obstructive azoospermia	A condition where there is no measurable sperm detected in the semen due to ejaculatory dysfunction or ductal blockage. This condition can occur in people with cystic fibrosis
Pancreatic exocrine insufficiency	A condition characterized by deficiency of the pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion
Salt-loss syndromes	A condition found in people with cystic fibrosis where there is loss of salt resulting in depletion of salt in the body
Septicaemia	A condition characterized by the widespread destruction of tissues due to absorption of disease containing bacteria or their toxins from the bloodstream

For further statistical terms, please refer to the The Cochrane Collaboration Glossary (http://cochrane.org/glossary).
For technical or clinical terms, please refer to The Human Genetics Commission Glossary (http://webarchive.nationalarchives.gov.uk/20100419143351/hgc.gov.uk/client/content.asp?contentid=729).

Appendix 2. MEDLINE search strategy (1970 to 10 December 2014)

Ovid MEDLINE(R) Daily Update
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)
1. exp Thalassemia/
2. thalass?emia.ti,ab,ot,hw.
3. ((erythroblastic or erythro-blastic or hypochromic or cooley$ or mediterranean) adj2 an?emia$).ti,ab,ot,hw.
4. (h?emoglobin adj2 disease$).ti,ab,ot,hw.
5. exp Hemoglobinopathies/
6. hereditary persistence of f?etal h?emoglobin.ti,ab,ot,hw.
7. (h?emoglobin adj2 (H or F or D or E) adj2 disease$).ti,ab,ot,hw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Anemia, Sickle Cell/
10. Sickle Cell Disease.ti,ab,ot,hw.
11. (sickle cell adj2 (an?emia$ or disease$ or disorder$)).ti,ab,ot,hw.
12. (h?emoglobin adj2 (S or C or SC)).ti,ab,ot,hw.
13. ((drepanocytosis or drepanocytic) adj2 an?emia).ti,ab,ot,hw.
14. 9 or 10 or 11 or 12 or 13
15. Cystic Fibrosis/
16. cystic fibrosis.ti,ab,ot,hw.
17. CF.ti,ab.
18. mucoviscidosis.ti,ab,ot,hw.
19. (fibrocystic adj3 disease$).ti,ab,ot,hw.
20. (pancreas$ adj2 (fibrosis or cystic disease$)).ti,ab,ot,hw.
21. 15 or 16 or 17 or 18 or 19 or 20

22. Tay-Sachs Disease/

23. Tay Sachs.ti,ab,ot,hw.

24. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.

25. TSD.ti,ab.

26. (GM2 adj2 gangliosidosis).ti,ab,ot,hw.

27. 22 or 23 or 24 or 25 or 26

28. Heterozygote/

29. trait$.ti,ab,ot,hw.

30. carrier$.ti,ab,ot,hw.

31. 28 or 29 or 30

32. 8 or 14 or 21 or 27 or 31

33. (Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$).ti,ab,ot,hw.

34. Maternal Health Services/

35. ((pregnan$ or conception or family) adj3 plan$).ti,ab,ot,hw.

36. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.

37. ((Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.

38. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.

39. 33 or 34 or 35 or 36 or 37 or 38

40. (carrier$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.

41. (genetic$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.

42. (heterozygot$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.

43. Genetic Services/

44. family history.ti,ab,ot,hw.

45. 40 or 41 or 42 or 43 or 44

46. (h?emoglobin adj2 electrophoresis).ti,ab,ot,hw.

47. Cystic Fibrosis Transmembrane Conductance Regulator/ or sweat test.ti,ab,ot,hw.

48. ((CFTR gene mutation$ or CFTR mutation$ or Hexoaminidase-A or Hexoaminidase A or HEX-A or H?emoglobin F or H?emoglobin A2 or H?emoglobin S) adj3 (test$ or analys$ or screen$ or profil$)).ti,ab,ot,hw.

49. 46 or 47 or 48

50. 32 or 45 or 49

51. 39 and 50

52. exp animals/ not humans.sh.

53. 51 not 52

54. limit 53 to yr="1970-Current"

Appendix 3. PsycINFO search strategy (1970 to 10 December 2014)

1. thalassemia.ti,ab,ot,hw.

2. thalassaemia.ti,ab,ot,hw.

3. ((erythroblastic or erythro-blastic or hypochromic or cooley* or mediterranean) adj2 anaemia*).ti,ab,ot,hw.

4. ((erythroblastic or erythro-blastic or hypochromic or cooley* or mediterranean) adj2 anemia*).ti,ab,ot,hw.

5. ((haemoglobin or hemoglobin) adj2 disease*).ti,ab,ot,hw.

6. ((haemoglobin or hemoglobin) adj2 (H or F or D or E) adj2 disease*).ti,ab,ot,hw.

7. 1 or 2 or 3 or 4 or 5 or 6

8. Sickle Cell Disease/

9. (sickle cell adj2 (anaemia* or disease* or disorder*)).ti,ab,ot,hw.

10. ((haemoglobin or hemoglobin) adj2 (S or C or SC)).ti,ab,ot,hw.

11. 8 or 9 or 10

12. Cystic Fibrosis/

13. cystic fibrosis.ti,ab,ot,hw.

14. CF.ti,ab.

15. mucoviscidosis.ti,ab,ot,hw.
16. (fibrocystic adj3 disease*).ti,ab,ot,hw.
17. 12 or 13 or 14 or 15 or 16
18. Tay Sachs Disease/
19. Tay Sachs.ti,ab,ot,hw.
20. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.
21. TSD.ti,ab.
22. (GM2 adj2 gangliosidosis).ti,ab,ot,hw.
23. 18 or 19 or 20 or 21 or 22
24. heterozygote.ti,ab,ot,hw.
25. trait*.ti,ab,ot,hw.
26. carrier*.ti,ab,ot,hw.
27. 24 or 25 or 26
28. 7 or 11 or 17 or 23 or 27
29. (Preconcept* or Pre-concept* or Prepregnan* or Pre-pregnan*).ti,ab,ot,hw.
30. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.
31. maternal health service*.ti,ab,ot,hw.
32. maternal care.ti,ab,ot,hw.
33. ((pregnan* or conception or family) adj3 plan*).ti,ab,ot,hw.
34. ((Preconcept* or Pre-concept* or Prepregnan* or Pre-pregnan*) adj2 (care or counsel* or advice* or advise or inform*)).ti,ab,ot,hw.
35. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel* or advice* or advise or inform*)).ti,ab,ot,hw.
36. 29 or 30 or 31 or 32 or 33 or 34 or 35
37. (genetic* adj3 (screen* or test* or counsel* or assess* or detect* or diagnos* or inform* or analys*)).ti,ab,ot,hw.
38. (carrier* adj3 (screen* or test* or counsel* or assess* or detect* or diagnos* or analys*)).ti,ab,ot,hw.
39. (heterozygot* adj3 (screen* or test* or counsel* or assess* or detect* or diagnos* or analys*)).ti,ab,ot,hw.
40. genetic service*.ti,ab,ot,hw.
41. family history.ti,ab,ot,hw.
42. 37 or 38 or 39 or 40 or 41
43. ((haemoglobin or hemoglobin) adj2 electrophoresis).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]
44. Cystic Fibrosis Transmembrane Conductance Regulator/ or sweat test.mp.
45. 43 or 44
46. 28 or 42 or 45
47. 36 and 46
48. exp Animals/
49. human.mp.
50. 48 and 49
51. 48 not 50
52. 47 not 51
53. limit 52 to yr="1970-Current"

Appendix 4. Embase search strategy (1974 to 06 January 2014)

1. exp thalassemia/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
2. exp delta thalassemia/ or exp beta thalassemia/ or exp thalassemia major/ or exp alpha thalassemia/ or exp thalassemia intermedia/ or exp sickle cell beta thalassemia/ or exp thalassemia minor/
3. thalass?emia.ti,ab,ot,hw.
4. ((erythroblastic or erythro-blastic or hypochromic) adj2 an?mia$).ti,ab,ot,hw.
5. (h?emoglobin adj2 disease$).ti,ab,ot,hw.
6. hemoglobinopathy/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
7. hereditary persistence of f?etal h?emoglobin.ti,ab,ot.
8. (h?emoglobin adj2 (h or d or e) adj2 disease$).ti,ab,ot,hw.

9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp sickle cell anemia/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
11. sickle cell disease.ti,ab,ot,hw.
12. (h?emoglobin adj2 (s or c)).ti,ab,ot,hw.
13. 10 or 11 or 12
14. exp cystic fibrosis/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
15. cystic fibrosis.ti,ab,ot,hw.
16. CF.ti,ab.
17. 14 or 15 or 16
18. exp Tay Sachs disease/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
19. Tay Sachs.ti,ab,ot,hw.
20. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.
21. TSD.ti,ab.
22. 18 or 19 or 20 or 21
23. exp heterozygote/ or exp heterozygote detection/
24. trait$.ti,ab,ot,hw.
25. carrier$.ti,ab,ot,hw.
26. 23 or 24 or 25
27. 9 or 13 or 17 or 22 or 26
28. (Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$).ti,ab,ot,hw.
29. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.
30. ((pregnan$ or conception or family) adj3 plan$).ti,ab,ot,hw.
31. ((Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
32. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
33. 28 or 29 or 30 or 31 or 32
34. (carrier$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
35. (genetic$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
36. (heterozygot$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
37. Genetic Service$.ti,ab,ot,hw.
38. family history.ti,ab.
39. 34 or 35 or 36 or 37 or 38
40. (h?emoglobin adj2 electrophoresis).ti,ab,ot,hw.
41. Cystic Fibrosis Transmembrane Conductance Regulator.ti,ab,ot,hw.
42. sweat test.ti,ab.
43. ((CFTR gene mutation$ or CFTR mutation$ or Hexoaminidase-A or Hexoaminidase A or HEX-A or H?emoglobin F or H?emoglobin A2 or H?emoglobin S) adj3 (test$ or analys$ or screen$ or profil$)).ti,ab,ot,hw.
44. 40 or 41 or 42 or 43
45. 27 or 39 or 44
46. 33 and 45
47. animal/
48. human/
49. 47 and 48
50. 47 not 49
51. 46 not 50
52. limit 51 to yr="1970-Current"

Appendix 5. CINAHL search strategy (1970 to 10 December 2014)

SI. (MH "Thalassemia") OR (MH "beta-Thalassemia") OR (MH "alpha-Thalassemia") OR (MH "delta-Thalassemia")
S2. (MH "Hemoglobinopathies")
S3. (MM "Anemia, Hypochromic")
S4. (MH "Anemia, Sickle Cell") OR (MH "Sickle Cell Trait")
S5. (MH "Cystic Fibrosis") OR "mucoviscidosis"
S6. (MH "Tay-Sachs Disease")
S7. (MH "Prepregnancy Care")
S8. (MH "Genetic Screening")
S9. (MH "Family Assessment") OR (MH "Family History")
S10. "hemoglobin electrophoresis"
S11. "cystic fibrosis transmembrane conductance regulator"
S12. "sweat test"
S13. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S8 OR S9 OR S10 OR S11 OR S12
S14. S7 AND S13
S15. Limiters - Published Date from: 19700101-current

CONTRIBUTIONS OF AUTHORS

Writing the protocol: all authors

Developing the search strategy: NH, NQ, JK and other (not review authors)

Searching for trials: NH and NQ

Selection of trials: NH, NQ, SW and other (not review authors)

Data entry: NH, SW

Analysis: NH, NQ, SW and JK

Interpret analysis: all authors

Draft final review: all authors

Update the review: NH and NQ

DECLARATIONS OF INTEREST

SOURCES OF SUPPORT

Internal sources

- University of Nottingham, UK.

computer, internet access

External sources

- National Institute for Health Research, UK.

This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Hand searching of key journals was originally specified from 1984 to date in the protocol. In the review, hand searching was conducted from 1998 to date for the *European Journal of Human Genetics* and *Genetics in Medicine* and from 2010 to date for the *Journal of Community Genetics*. This change was made because these were the earliest dates that the online table of contents were accessible for these key journals.

INDEX TERMS

Medical Subject Headings (MeSH)

*Genetic Carrier Screening; *Preconception Care; Anemia, Sickle Cell [*genetics]; Cystic Fibrosis [*genetics]; Risk Assessment; Tay-Sachs Disease [*genetics]; Thalassemia [*genetics]

MeSH check words

Female; Humans